Physician profile
Eric Renicker
NPI 1679629513
$1,558.24
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,298 · 2022: $115 · 2024: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $211.19 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $192.50 | 2021 | |
| Alkermes, INC. | $185.23 | 2021-2022 | |
| Abbvie INC. | $171.43 | 2021-2022 | |
| Uswm, LLC | $166.04 | 2021-2024 | Lucemyra |
| Neurocrine Biosciences, INC. | $144.48 | 2021 | |
| Vanda Pharmaceuticals INC. | $143.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $131.18 | 2024 | Cobenfy |
| Lundbeck LLC | $58.76 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $39.41 | 2021 | |
| Noven Therapeutics, LLC | $38.57 | 2021 | |
| Indivior INC. | $24.05 | 2021 | |
| Almatica Pharma LLC | $19.04 | 2022 | |
| Eisai INC. | $18.93 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Renicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.